Lobbying disclosures · Lobbying report
MDGL: second_quarter 2026 lobbying report
Issues related to CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models). Issues related to drug pricing; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Section 301 tariffs.
Follow MDGL- Became public
- Jul 19, 2026, 9:22 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 10, 2026, 5:43 AM EST
Why this is connected
Exact legal-name match: MADRIGAL PHARMACEUTICALS, INC. (https://www.sec.gov/Archives/edgar/data/1157601/).
Reported lobbying amounts
Income: $50,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/f7d6b5ba-04b4-4652-84c8-fc867826af66/","filing_uuid":"f7d6b5ba-04b4-4652-84c8-fc867826af66","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/f7d6b5ba-04b4-4652-84c8-fc867826af66/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Mathew Lapinski","dt_posted":"2026-07-19T21:22:06-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"800 North Capitol Street, NW, Suite 800","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20002","registrant":{"id":400531586,"url":"https://lda.gov/api/v1/registrants/400531586/","house_registrant_id":null,"name":"CROSSROADS STRATEGIES, LLC","description":"lobbying firm","address_1":"800 North Capitol Street, NW, Suite 800","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20002","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MATHEW LAPINSKI","contact_telephone":"+1 202-559-0170","dt_updated":"2026-07-30T15:56:39.212913-04:00"},"client":{"id":68999,"url":"https://lda.gov/api/v1/clients/68999/","client_id":68999,"name":"MADRIGAL PHARMACEUTICALS, INC.","general_description":"biopharmaceutical company","client_government_entity":null,"client_self_select":false,"state":"PA","state_display":"Pennsylvania","country":"US","country_display":"United States of America","ppb_state":"PA","ppb_state_display":"Pennsylvania","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-07-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":58561,"prefix":null,"prefix_display":null,"first_name":"MATHEW","nickname":null,"middle_name":null,"last_name":"LAPINSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143773,"prefix":"ms","prefix_display":"MS.","first_name":"CHERYL","nickname":null,"middle_name":"LYNN","last_name":"JAEGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66496,"prefix":null,"prefix_display":null,"first_name":"JASON","nickname":null,"middle_name":"BENJAMIN","last_name":"VAN PELT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151117,"prefix":"mr","prefix_display":"MR.","first_name":"STEPHEN","nickname":null,"middle_name":"THOMAS","last_name":"VOLJAVEC","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to drug pricing; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Section 301 tariffs.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":58561,"prefix":null,"prefix_display":null,"first_name":"MATHEW","nickname":null,"middle_name":null,"last_name":"LAPINSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143773,"prefix":"ms","prefix_display":"MS.","first_name":"CHERYL","nickname":null,"middle_name":"LYNN","last_name":"JAEGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66496,"prefix":null,"prefix_display":null,"first_name":"JASON","nickname":null,"middle_name":"BENJAMIN","last_name":"VAN PELT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151117,"prefix":"mr","prefix_display":"MR.","first_name":"STEPHEN","nickname":null,"middle_name":"THOMAS","last_name":"VOLJAVEC","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in MDGL
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- May 19, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
Sold Madrigal Pharmaceuticals MDGL
$1K–$15K · Traded Apr 10, 2023 · disclosed May 19, 2023
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.